Diffuse Intrinsic Pontine Glioma Clinical Trial
Official title:
Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma
This is a Phase I clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Status | Completed |
Enrollment | 25 |
Est. completion date | June 2014 |
Est. primary completion date | April 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Months to 21 Years |
Eligibility |
Inclusion Criteria: 1. Age must be = 18 months and < 21 years 2. Diagnosis of DIPG or high-grade glioma originating from the brainstem. 3. Lansky (for research participants = 16 years) or Karnofsky (for research participants > 16 years) performance score = 40 at the time of study enrollment 4. Adequate organ function at the time of study enrollment as follows: - Bone marrow: ANC = 1,000/µL, platelet count = 100,000/µL (transfusion independent), hemoglobin concentration = 8g/dL (may be transfused) - Renal: Serum creatinine concentration < 2x the institutional normal values for age or GFR > 70ml/min/1.73m2 - Hepatic: Total bilirubin concentration < 1.5x the institutional upper limit of normal for age; SGPT < 5x the institutional upper limit of normal; albumin = 2 g/dL 5. Electrocardiogram (EKG) with an average QTc interval < 450 msec. If a research participant has QTc interval = 450 msec on screening EKG, the screening EKG may be repeated twice (at least 24 hours apart). The average QTc interval from the three screening EKGs must be < 450 msec in order for the research participant to be eligible for the study. Research participants with abnormal serum electrolytes and a QTc interval = 450 msec should have a repeat EKG repeated once the concentration of serum electrolyte is corrected 6. Female research participants of childbearing age must not be pregnant (confirmed by serum or urine pregnancy test within 1 week of treatment start) or breast-feeding. 7. Female research participants of childbearing age and male research participants of child fathering potential must agree to use safe contraceptive methods Exclusion Criteria: 1. Metastatic disease 2. Use of enzyme-inducing anticonvulsants 3. Research participants who received any other type of anticancer treatment 4. Research participants with uncontrolled infection 5. Research participants with any concomitant significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy, or that would impair the evaluation of side effects related to this treatment, alter drug metabolism or the tolerance to this treatment 6. QTc interval prolongation with other medications that required discontinuation of that medication 7. Research participants with any history of cardiac arrhythmias or congenital long QT syndrome 8. Use of any concomitant medication that may cause QT interval prolongation and/or induce Torsades de Pointes 9. Hypertension defined as systolic and/or diastolic blood pressure > 95th percentile for age, height and gender, or blood pressure > 140/90 for research participants = 18 years of age. If hypertension is detected, blood pressure values < 95th in two separate occasions need to be documented before registration. Body surface = 1.8m2 for research participants enrolled on dosage levels 2, 3, and 4 |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | AstraZeneca, The Cure Starts Now Foundation, Tyler's Treehouse |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To estimate the maximum tolerated dose (MTD) of the combination of vandetanib and dasatinib administered concurrently with RT in pediatric research participants with newly diagnosed DIPG | April 2012 | Yes | |
Secondary | To determine the toxicities associated with the chronic use of vandetanib and dasatinib | July 2012 | Yes | |
Secondary | To characterize the pharmacokinetics of vandetanib and dasatinib in pediatric research participants | July 2012 | No | |
Secondary | To evaluate the influence of specific polymorphisms (e.g., CYP3A4/5) on the pharmacokinetics of vandetanib and dasatinib administered in combination | July 2012 | No | |
Secondary | To explore the association between plasma angiogenic factors and response to current therapy | July 2012 | No | |
Secondary | To evaluate the pharmacodynamics of dasatinib in target receptors and pathways in peripheral mononuclear cells | July 2012 | No | |
Secondary | To describe the research participants' and parents' perspective of the quality of life of children with newly diagnosed DIPG enrolled on this phase I trial | July 2012 | No | |
Secondary | To describe the quality of life of parents of pediatric research participants with newly diagnosed DIPG enrolled on this phase I trial | July 2012 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
Recruiting |
NCT05476939 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
|
Phase 3 | |
Terminated |
NCT03330197 -
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
|
Phase 1/Phase 2 | |
Terminated |
NCT03690869 -
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02992015 -
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
|
Early Phase 1 | |
Terminated |
NCT01182350 -
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
|
Phase 2 | |
Recruiting |
NCT04837547 -
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04911621 -
Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06333899 -
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
|
Early Phase 1 | |
Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
Active, not recruiting |
NCT02420613 -
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
|
Phase 1 | |
Completed |
NCT03086616 -
CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)
|
Phase 1 | |
Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06093165 -
RE-irradiation of Diffuse MIdline Glioma paTients
|
N/A | |
Withdrawn |
NCT03632317 -
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
|
Phase 2 | |
Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
Recruiting |
NCT02233049 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
|
Phase 2 | |
Recruiting |
NCT05009992 -
Combination Therapy for the Treatment of Diffuse Midline Gliomas
|
Phase 2 | |
Recruiting |
NCT04049669 -
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
|
Phase 2 | |
Recruiting |
NCT05298995 -
GD2-CAR T Cells for Pediatric Brain Tumours
|
Phase 1 |